Denali: ALS Phase 1b Data in ALS To Be Presented at Upcoming AAN Meet

 

• Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)
• Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution and support once-daily dosing
• Initiation of DNL343 regimen in the Phase 2/3 HEALEY ALS Platform Trial is expected in mid 2023

https://www.biospace.com/article/releases/denali-therapeutics-announces-new-dnl343-eif2b-agonist-phase-1b-data-in-als-to-be-presented-at-the-upcoming-aan-annual-meeting/